AIM ImmunoTech Inc. AIM

AIM ImmunoTech says Ampligen has a distinct mechanism from the FDA approved daraxonrasib and could play both complementary and standalone roles in metastatic pancreatic cancer. The company notes daraxonrasib produced a median overall survival of 13.2 months versus 6.7 months with standard chemotherapy in NEJM data, while Ampligen is a Toll-like receptor 3 agonist intended to activate innate immunity and reshape the tumor microenvironment. In a Dutch Named Patient Program, Ampligen as monotherapy reportedly correlated with a median OS of 34.8 months vs 12.5 months for matched controls. AIM highlights ongoing Phase 2 DURIPANC at least in combination with AstraZeneca’s durvalumab in patients stable after FOLFIRINOX, with topline results due in Q1 2027 and OS analyses in Q3 2027, aiming to set the stage for a potential pivotal trial. Ampligen’s potential to complement or replace existing therapies, if future trial results validate its OS signals, could materially alter AIM's trajectory.

AIM ImmunoTech released a CEO Corner video highlighting scientific rationale, supportive data, and ongoing advancement of Ampligen in pancreatic cancer treatment. CEO video on Ampligen pancreatic cancer progress signals pipeline updates likely to affect near-term sentiment without major new catalysts.

AIM ImmunoTech expands Ampligen patent estate with Long COVID protection across Europe and United Kingdom through 2041. Patent expansion grants long-term exclusivity in major markets enhancing competitive position and revenue outlook.

AIM ImmunoTech secures a broad U.S. patent for rintatolimod (Ampligen) used in combination with pembrolizumab (Keytruda), extending oncology IP protection for Ampligen through 2039. Extended patent protection for Ampligen in oncology combinations strengthens AIM's competitive position and IP assets through 2039.

Aimia Q2 earnings call highlights financial results and operational updates for AIM ImmunoTech Inc. Q2 earnings details offer updates on performance that may shift near-term investor sentiment without major strategic shifts.

AIMIA reports second quarter 2026 results. Quarterly results release can moderately influence investor views on financial health and outlook.

AIM ImmunoTech Inc. advances ahead of schedule to administer the final dose in its DURIPANC clinical trial, reaching a key inflection point in the study. Ahead-of-schedule completion of a critical clinical milestone strengthens development timeline and supports positive trajectory for the company's lead program.

AIM ImmunoTech releases new CEO Corner segment highlighting growing momentum across pancreatic cancer program. CEO segment on pancreatic cancer momentum offers moderate positive visibility for core program without major clinical or financial shifts.

AIM ImmunoTech advances Ampligen through clinical milestones toward a potential pivotal pancreatic cancer program. Progress of Ampligen toward pivotal pancreatic cancer program can significantly alter company trajectory via potential regulatory and market gains.

AIM ImmunoTech completed first dosing of the final subject in its Phase 2 DURIPANC study for metastatic pancreatic cancer. Phase 2 enrollment completion advances AIM's pancreatic cancer drug development without immediate revenue or approval impact.

AIM ImmunoTech Inc. announces $2.65 million financing priced at-market under NYSE American Rules. $2.65 million at-market financing supplies capital to support operations and may influence near-term financial position.

AIM ImmunoTech reports positive mid-year interim clinical progress from Phase 2 study of Ampligen combined with AstraZeneca's Imfinzi for pancreatic cancer treatment. Positive Phase 2 interim data on Ampligen-Imfinzi combination advances pancreatic cancer program and strengthens pipeline outlook.

AIM ImmunoTech Inc. stock surged 42% after pancreatic cancer trial hit key enrollment milestone ahead of schedule. CEO signals significant value-inflection period ahead. Positive trial enrollment milestone directly boosts clinical progress and investor sentiment for core oncology program.

AIM ImmunoTech completed Phase 2 DURIPANC enrollment ahead of schedule, advancing Ampligen toward pancreatic cancer clinical milestones. Early Phase 2 enrollment completion accelerates Ampligen development timeline and boosts prospects in pancreatic cancer.

AIM ImmunoTech identifies Ampligen as candidate for Ebola treatment amid WHO emergency declaration and rising global health concerns. Potential new Ebola use for Ampligen can drive significant strategic expansion and investor interest for AIM.

AIM ImmunoTech raises $2.4 million via concurrent registered direct offering and private placement. The $2.4 million financing strengthens AIM ImmunoTech cash reserves to support ongoing operations and development.

AIM ImmunoTech reports a significant rise in stockholder equity and extends promissory note maturity to June 2027, strengthening balance sheet flexibility to support ongoing clinical development priorities. Improved equity position and extended debt maturity reduce near-term financial risk and aid clinical execution but do not alter core product or market trajectory.

AIM ImmunoTech posts virtual investor Key Opinion Leader segment spotlighting breakthrough data for Ampligen in pancreatic cancer treatment. Breakthrough Ampligen data in pancreatic cancer highlights major pipeline advancement poised to significantly enhance AIM's oncology prospects and investor sentiment.

AIM ImmunoTech Inc. (AIM) released the transcript of its Q1 2026 earnings conference call. Q1 earnings conference call transcript discloses financial results, operational updates, and guidance influencing short-to-medium term market performance.

AIM ImmunoTech announces 50% objective response rate in UPMC Phase 2 clinical trial for recurrent ovarian cancer, suggesting breakthrough potential for combination therapy. 50% ORR in Phase 2 recurrent ovarian cancer trial signals major clinical progress that could drive partnerships, further trials, and substantial stock gains for AIM.

AIM ImmunoTech advances to pivotal value inflection phase with planned Phase 3 study of Ampligen for pancreatic cancer, supported by positive clinical signals, orphan drug status, and global intellectual property. Planned Phase 3 trial in pancreatic cancer with positive signals, orphan status, and global IP represents a major strategic advancement likely to boost investor sentiment and trajectory.

AIMIA provides update on its share buybacks. Share buyback updates signal management confidence and can moderately boost EPS and investor sentiment.

Thermo Fisher Scientific (TMO) partners with AIM ImmunoTech Inc. (AIM) on a Phase 3 cancer trial. Partnership with Thermo Fisher on Phase 3 cancer trial delivers major strategic validation, resources, and credibility boost to AIM's oncology pipeline.

AIM ImmunoTech Inc. (AIM) reported fourth quarter and full year 2025 financial results. Quarterly and annual earnings disclosures significantly affect financial performance perceptions and stock trajectory.

Aimia's Q4 earnings call highlights detailed financial results, operational updates, and forward guidance for AIM ImmunoTech Inc. Q4 earnings call highlights moderately impact AIM's financial performance and investor sentiment without fundamentally altering long-term trajectory.

AIM ImmunoTech Inc. announces final approval of a patent in Japan for a novel cancer therapy combining Ampligen with checkpoint inhibitors. Patent approval in Japan for Ampligen-checkpoint inhibitor combination bolsters IP protection and oncology market potential.

AIM ImmunoTech Inc. (AIM) closed its rights offering, enabling shareholders to purchase additional shares and providing the company with new capital. Closing the rights offering delivers critical funding to support AIM ImmunoTech's operations and development pipeline, significantly strengthening its financial position and investor confidence.

AIM ImmunoTech Inc. (AIM) signed an agreement to plan a proposed Phase 3 clinical trial of Ampligen for late-stage pancreatic cancer treatment. Agreement for Phase 3 trial planning advances Ampligen in oncology, potentially transforming AIM's pipeline and market position.

AIM ImmunoTech reminds stockholders of the March 3, 2026 expiration date for its rights offering and updates terms of the previously announced offering. Rights offering updates impact capital raising and potential share dilution, moderately affecting financial position and market sentiment.

AIM ImmunoTech announces planned milestones in the ongoing Phase 2 trial of Ampligen combined with AstraZeneca’s Durvalumab for metastatic pancreatic cancer treatment. Phase 2 trial milestones with AstraZeneca’s Durvalumab for hard-to-treat pancreatic cancer signal major strategic progress boosting AIM's investor sentiment and trajectory.